Discovering a New Treatment for MS and Ulcerative Colitis, Hugh Rosen, MD, PhD

Hugh Rosen, professor in the Department of Molecular Medicine at Scripps Research, uses chemical and biological approaches to define and manipulate the molecular gatekeepers regulating cell trafficking in the immune system. His research led to the discovery and development of ozanimod, a breakthrough drug acquired by Celgene, that slows brain atrophy in patients with multiple sclerosis and shows promise for treating ulcerative colitis and Crohn’s disease.

The inaugural Spectrum symposium, hosted on February 20, 2019 in La Jolla, California, convened thought leaders from across the country for discussions around accelerating delivery of novel medicines to the patients desperately in need of new therapies. Over 200 attendees-- foundation representatives, philanthropists, biopharma leaders, healthcare investors and research scientists-- listened to Scripps Research scientists share their basic and translational research efforts. The symposium inspired follow-up discussions about potential initiatives and collaborations to impact public health.

Видео Discovering a New Treatment for MS and Ulcerative Colitis, Hugh Rosen, MD, PhD канала Scripps Research